Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia.
about
Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopeniaBrief report: deficient thymic output in rheumatoid arthritis despite abundance of prethymic progenitorsThe role of B cells in solid organ transplantation.Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemiaLymphocytes as an Indicator for Initial Kidney Function: A Single Center Analysis of Outcome after Alemtuzumab or Basiliximab InductionModulating co-stimulation: a rational strategy in the treatment of rheumatoid arthritis?Development and validation of a risk score for serious infection in patients with rheumatoid arthritis.A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation.Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases.Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies.Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes.Novel immunotherapeutic approaches for allergy and asthma.Emerging drugs for the treatment of transplant rejection.Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity.Hepatitis B and C prophylaxis in patients receiving chemotherapy.Mycobacterium avium complex infection after alemtuzumab therapy for chronic lymphocytic leukemia.Update in the mechanisms of allergen-specific immunotheraphy.Outcome of intensive immunosuppression and autologous stem cell transplantation in patients with severe rheumatoid arthritis is associated with the composition of synovial T cell infiltration.Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation.Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study.[Personalized medicine for rheumatoid arthritis : serological and clinical patient profiles to optimize B and T cell targeted therapy].CD52 ligation induces CD4 and CD8 down modulation in vivo and in vitro.Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.Long-term survival after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis.
P2860
Q24798777-D6091EDA-50A3-4003-96EA-9C95D901FDB8Q33661636-EC8DBCF9-7BED-49D6-9E99-5A756B0059CEQ33891696-F35E46C5-9D3A-4F29-B66E-85F7BF1FAF63Q35669193-BF4C14B1-6022-40BB-800E-EBC549E0B97BQ35781773-CC2A9F66-2D57-4B1B-95D0-9B7AA3420C4CQ36099553-CA92CD53-AA4D-499B-9376-257F12AF01B9Q36179586-51E1195A-DD9E-4E39-8804-FBACB368C533Q36194538-6FFE9ABD-9ECD-41D9-A0A3-43A488A4782FQ36747670-47C514D5-ACF2-4F19-8CBE-ED7E15DE2DEDQ37518302-187E4E7B-2E86-4B78-975A-5F973548988FQ37603286-4B3DCB36-090E-4FF9-8D8F-51526D24632AQ37728000-CD35AC5C-5826-49F6-A766-1C249EDDB779Q37960177-9BCBC439-D1F3-406F-8E08-7AC18DB46AADQ38071110-156B61D6-8B18-4C4D-A1C7-9CDCD47CA6ADQ39683646-11256CDA-D23B-4065-806F-DFF1FB92C45EQ40130220-A8D0E1CC-1898-4BD6-9548-27B3E3AF9C4CQ41273420-C2BF1C2C-206B-4613-8F19-0332FB7B00D5Q41869348-28E02194-C1CB-4485-B6BD-E6280DB41BAEQ42502255-3BF1ED62-6923-4F39-BEE2-719E8C94D88AQ44461489-135CF7A8-7240-436D-94A1-31E89D7605CCQ52885796-4F0B00E5-083F-4667-90BA-D05152E5D782Q53604503-90A24164-A1FC-4ACB-BBA3-672C4A369B1CQ54146573-E2E39D1A-3F6D-4AA1-B241-A9E69F4DC5B6Q55641712-73A84D1F-D0CA-4078-9B3F-FAACF194D2C9
P2860
Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Morbidity and mortality in rhe ...... d therapy-induced lymphopenia.
@ast
Morbidity and mortality in rhe ...... d therapy-induced lymphopenia.
@en
Morbidity and mortality in rhe ...... d therapy-induced lymphopenia.
@nl
type
label
Morbidity and mortality in rhe ...... d therapy-induced lymphopenia.
@ast
Morbidity and mortality in rhe ...... d therapy-induced lymphopenia.
@en
Morbidity and mortality in rhe ...... d therapy-induced lymphopenia.
@nl
prefLabel
Morbidity and mortality in rhe ...... d therapy-induced lymphopenia.
@ast
Morbidity and mortality in rhe ...... d therapy-induced lymphopenia.
@en
Morbidity and mortality in rhe ...... d therapy-induced lymphopenia.
@nl
P2093
P2860
P1476
Morbidity and mortality in rhe ...... d therapy-induced lymphopenia.
@en
P2093
B L Hazleman
J D Isaacs
J Johnston
P2860
P304
P356
10.1002/1529-0131(200109)44:9<1998::AID-ART348>3.0.CO;2-T
P577
2001-09-01T00:00:00Z